MedMira Debuts New Brand Identity and Redesigned Company Website
HALIFAX, Nov. 2, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, has launched a new brand identity for the Company along with a redesigned website at www.medmira.com.
MedMira's new brand identity is designed to reflect its innovative mindset and its core focus on technology and high quality testing solutions. The logo symbol identifies with the Company name and the unique vertical flow-through technology that sets MedMira apart from other rapid diagnostics companies. The symbol also illustrates the advanced multiplex capabilities of MedMira's rapid testing solutions that deliver a minimum three test results on a single device. The new identity will also be applied to the Company's product portfolio of rapid testing solutions.
"We are proud to introduce this unique wordmark and symbol as part of our brand identity as it reflects the quality of our world class rapid vertical flow-through diagnostic technology and testing solutions," said Hermes Chan, CEO. "Our new look represents a key piece in a strategic transformation for the Company, as we go forward with a solid technology and product focus to deliver advanced rapid testing solutions to customers and value to our shareholders."
A central piece in MedMira's brand evolution is the redesigned and upgraded Company website, which boasts a new, modern look as well as quick and easy access to more in-depth product and company information. The new site includes product demonstration videos that illustrate how to use MedMira's rapid testing solutions in various environments, including point of care, laboratories and batch testing settings. These new videos are key sales and training tools for MedMira's partners and customers. The new website also includes an enriched section for investors, with an extensive Investor Kit. MedMira worked with the digital marketing agency, Headspace Design (www.headspacedesign.ca), to develop the new identity and website.
Chan added, "Working with partners, customers and key stakeholders around the world, we understand the importance of providing information about our products and our Company online. With this in mind we have launched our redesigned website to provide straightforward and relevant information about MedMira, our technology and products to a broad range of audiences, from customers to investors, to collaborators."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's testing solutions provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.For further information:
Andrea Young, Corporate Communications